Get the Stockscreener App
2.29
10.63%
0.22
After Hours:
2.27
-0.02
-0.87%
Fate Therapeutics Inc stock is traded at $2.29, with a volume of 3.61M.
It is up +10.63% in the last 24 hours and down -28.21% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$2.07
Open:
$2.1
24h Volume:
3.61M
Relative Volume:
2.21
Market Cap:
$260.82M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-1.0553
EPS:
-2.17
Net Cash Flow:
$-132.53M
1W Performance:
+13.37%
1M Performance:
-28.21%
6M Performance:
-37.26%
1Y Performance:
-4.18%
1-Day Range:
$2.07
$2.36
1-Week Range:
$2.01
$3.50
52-Week Range:
$1.96
$8.83
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| FATE | 2.29 | 260.82M | 13.45M | -178.23M | -132.53M | -2.17 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - Defense World
Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN
Needham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Thera rockets on early data for FT819 - The Pharma Letter
Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com
BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Fate Therapeutics Presents 6-Month Follow-up Data on First - GlobeNewswire
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Yahoo Finance
Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges - TipRanks
Fate Therapeutics Unveils Q3 2024 Financial Highlights - TipRanks
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance
BMO cuts Fate Therapeutics stock target, keeps market rating on initial data - Investing.com UK
Fate Therapeutics: Q3 Earnings Snapshot - CT Insider
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - The Manila Times
Fate Therapeutics Highlights Cancer-selective, - GlobeNewswire
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewswire Inc.
Fate Therapeutics Presents Pan-tumor Targeting Preclinical - GlobeNewswire
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Inc (FATE) Worth Considering For The Next Few Weeks - Stocks Register
Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register
Global T-cell Therapy Market Trend [2024-2032] | Consumer Demographics - WICZ
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat
Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News
Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News
Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat
Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily
Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News
Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):